Our results show that the use of oncolytic virus SVA carrying p16 would not affect its original oncolytic effect but would also lead to a sustained high expression of p16 in tumor cells with SVA infection, resulting in the effective killing of the infected cells quite effectively. The gene discussed is CDKN2A; the disease is infection.